Cargando…

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells

BACKGROUND: Hypoxia-inducible factor 1 (HIF1) has been implicated in regulating many of the genes responsible for angiogenesis, erythropoiesis, glucose metabolism and cancer pathogenesis. In this study, we demonstrate that exposure of human breast cancer lines to 17β-oestradiol (E2) rapidly induced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sudhagar, S, Sathya, S, Lakshmi, B S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185958/ https://www.ncbi.nlm.nih.gov/pubmed/21897387 http://dx.doi.org/10.1038/bjc.2011.349

Ejemplares similares

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235)
por: Trauger, R, et al.
Publicado: (2009)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
por: Zuo, M, et al.
Publicado: (2015)

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
por: Jimeno, A, et al.
Publicado: (2007)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
por: Makhov, P, et al.
Publicado: (2014)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
por: Liu, Weiwei, et al.
Publicado: (2017)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
por: Presneau, N, et al.
Publicado: (2009)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
por: García-Martínez, J M, et al.
Publicado: (2011)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination
por: Huang, H, et al.
Publicado: (2014)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer
por: Qin, R, et al.
Publicado: (2015)

17β-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response
por: Chinje, E C, et al.
Publicado: (2002)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Differential pattern of HIF-1α expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect
por: Wozny, Anne-Sophie, et al.
Publicado: (2017)

The neuro-steroid, 3β androstene 17α diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways
por: Graf, M R, et al.
Publicado: (2007)

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells
por: Carbajo-Pescador, S, et al.
Publicado: (2013)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy
por: Harada, H, et al.
Publicado: (2009)

Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells
por: Mancini, M, et al.
Publicado: (2014)

Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion
por: Siret, Carole, et al.
Publicado: (2015)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_97sc5cna29k26u3ojfoqla8pms